Physician profile
Joanne Preston
NPI 1417037748
$6,213.38
in general payments reported to CMS, 2019-2025
24 companies · $2,464 in 2025
The $2,464 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $451 · 2023: $1,366 · 2024: $1,569 · 2025: $2,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,752 · Travel and Lodging: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,752.33 |
| Travel and Lodging | $646.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,334.37 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,230.23 | 2021-2025 | Ozempic, Rybelsus, Sogroya |
| Medtronic, INC. | $842.87 | 2025 | Minimed 780g, Simplera Sensor |
| Bayer Healthcare Pharmaceuticals INC. | $694.75 | 2023-2025 | |
| Amgen INC. | $354.83 | 2023-2025 | Tepezza, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $333.26 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $292.38 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $190.26 | 2023-2025 | |
| Corcept Therapeutics | $188.59 | 2023-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.30 | 2023-2025 | Jardiance |
| Dexcom, INC. | $100.19 | 2024-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $70.81 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $56.50 | 2023-2025 | Tymlos |
| Esperion Therapeutics, INC. | $53.35 | 2024-2025 | Nexletol |
| Chiesi USA, INC. | $53.22 | 2024 | Mycapssa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49.80 | 2024 | |
| Recordati_rare_diseases_inc. | $49.54 | 2025 | Isturisa |
| Insulet Corporation | $39.61 | 2023 | Omnipod |
| Amneal Pharmaceuticals LLC | $30.51 | 2024-2025 | Unithroid |
| Abbott Laboratories | $22.71 | 2025 | Eterna |
| Averitas Pharma INC. | $21.66 | 2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $21.05 | 2023 | Strensiq |
| Kyowa Kirin, INC. | $16.37 | 2023 | Crysvita |
| Tolmar, INC. | $16.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Preston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.